Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
June 25, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data...
Alpha Tau to Present at the Jefferies Global Healthcare Conference
May 21, 2024 08:45 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 20, 2024 16:01 ET
|
Alpha Tau Medical Ltd.
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a...
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
May 13, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
May 06, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both...
Alpha Tau to Participate in May Investor Conferences
May 01, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
March 25, 2024 08:50 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024 16:01 ET
|
Alpha Tau Medical Ltd.
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently...
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
February 26, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023 09:15 ET
|
Alpha Tau Medical Ltd.
- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well...